Nexalin Technology, Inc. NXL 深 沪

Nexalin Technology Q4 EPS $(0.13) Misses $(0.12) Estimate, Sales $171.895K Beat $80.000K Estimate

Nexalin Technology (NASDAQ:NXL) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 53.57 percent increase over losses of $(0.28) per share

03-26 06:09

Nexalin Advances Pivotal HALO Clarity Trial for Insomnia

An update from Nexalin Technology, Inc. ( ($NXL) ) is now available. On Februar...

02-26 03:58

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease. Nexalin Technology, Inc. commended recent bipartisan Congressional initiatives expanding federal focus on deep brain neurostimulation and related neuromodulation research within the U.S. Department of Veterans Affairs (VA) and the National Institutes of Health (NIH). Nexalin’s DIFS™ techno...

02-23 13:18

Nexalin Technology Validates DIFS™ Neurostimulation with New Clinical Research Across Multiple Brain Disorders

Nexalin Technology Validates DIFS™ Neurostimulation with New Clinical Research Across Multiple Brain Disorders Nexalin Technology Inc. has highlighted new peer-reviewed clinical research validating its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology across multiple neurologica

02-02 21:45

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

02-02 13:45

Nexalin Notified Recieves NASDAQ Minimum Bid Price Deficiency Letter, Has Until July 20, 2026 To Comply

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification

01-24 06:22

Nexalin Technology Receives Nasdaq Listing Status Notification

<p>Nexalin Technology, Inc. (Nasdaq: NXL) has received a notification from NASDAQ indicating non-compliance with the minimum bid price requirement of US$1.00 per share under Listing Rule 5550(a)(2). The company has 180 days until July 20, 2026, to regain compliance by achieving a closing bid price of at least US$1.00 for 10 consecutive trading days. Failure to meet this requirement may result in delisting. Nexalin is monitoring its bid price and ...

01-23 22:15

Nexalin Technology Announces Publication Of New Peer-Reviewed Clinical Study In Molecular Psychiatry Demonstrating DIFS Technology Improves Attention And Normalizes Brain Activity In Patients With ADHD

Nexalin Technology, Inc. (NASDAQ:NXL) (the &#34;Company&#34; or &#34;Nexalin&#34;), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed

01-14 22:04

Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Nexalin Technology announced the publication of a study in *Molecular Psychiatry* showcasing their DIFS™ neurostimulation technology's effectiveness in improving ADHD symptoms and brain function in adults. The randomized, double-blind trial of 56 adults showed a 10.1-point improvement in ADHD symptoms compared to a 5.5-point improvement in the sham group. Advanced neuroimaging revealed reduced excessive gamma activity and improved brain network c...

01-14 14:00

Nexalin Advances Non-Invasive Alzheimer's Therapy Toward FDA Clinical Trials

Nexalin Technology Inc. has announced progress in its research and development efforts for the treatment of Alzheimer's disease. The company recently held a Q-Sub meeting with the FDA, during which th...

2025-12-03 21:03